Fukuoka, Japan

Masato Murai

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignee: Api Corporation. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masato Murai. Retrieved from https://idiyas.com/inventor/masato-murai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 100.0


 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Fukuoka, JP (2017 - 2020)
  • Tokyo, JP (2024)

Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Masato Murai is a prolific inventor and patent holder who hails from Fukuoka, Japan. He currently works at API Corporation, a company that specializes in the production of active pharmaceutical ingredients. Murai has made significant contributions to the field, and his latest patents include a method for producing 5-hydroxypiperidine-2-carboxylic acid. This solution involves removing the protecting group from the hydroxyl group in a compound to synthesize it.

Mura has a total of 5 patents to his name and has worked with some of his colleagues on these projects, including Tomoko Maeda and Jun Takehara. The two are also involved in the research and development of active pharmaceutical ingredients.

Murai's expertise and years of experience in this field have proven to be invaluable to API Corporation, and he continues to work on innovative solutions aimed at improving drug production processes. His research work will undoubtedly impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…